Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TECZEM vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Enalapril inhibits angiotensin-converting enzyme (ACE), reducing angiotensin II formation, leading to vasodilation and decreased aldosterone secretion. Diltiazem inhibits calcium ion influx across cardiac and smooth muscle cells, causing coronary vasodilation and decreased myocardial contractility.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Hypertension,Stable angina,Chronic stable angina
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
1 to 2 tablets (enalapril 5 mg/diltiazem 180 mg) orally once daily. Maximum: 2 tablets daily.
250 mg orally twice daily
Terminal elimination half-life: 3-4 hours for diltiazem; clinical context: requires twice-daily dosing due to short half-life.
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Enalapril is hydrolyzed to active enalaprilat, mainly hepatically. Diltiazem is extensively metabolized in the liver via CYP3A4.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Renal: 40-50% unchanged; hepatic/biliary/fecal: 50-60% as metabolites.
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
70-80% bound to albumin and alpha-1-acid glycoprotein.
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
5-7 L/kg; indicates extensive tissue distribution.
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Oral: 35-60% due to first-pass metabolism; IV: 100%.
70-90% (oral); 100% (IV).
GFR >30 m L/min: No adjustment. GFR 10-30 m L/min: Use with caution, monitor potassium and creatinine. GFR <10 m L/min: Avoid use.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
Child-Pugh A: No adjustment. Child-Pugh B: Use with caution, consider starting at lowest dose. Child-Pugh C: Contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Safety and efficacy not established for patients <18 years.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
Start at lowest dose, monitor renal function and electrolytes due to age-related decreased renal function and increased sensitivity.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
Use in pregnancy: ACE inhibitors can cause injury and death to the developing fetus. Discontinue as soon as possible when pregnancy is detected.
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
Hypotension,Angioedema,Hepatic injury,Heart block,Bradycardia,Renal impairment,Hyperkalemia
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Hypersensitivity to enalapril, diltiazem, or any component,History of angioedema related to ACE inhibitors,Second- or third-degree AV block (except with pacemaker),Sick sinus syndrome,Severe hypotension,Cardiogenic shock,Concurrent use with riociguat
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
Avoid high-potassium foods (e.g., bananas, oranges, spinach) due to potential for hyperkalemia from enalapril. Grapefruit juice may increase diltiazem levels and should be limited or avoided. Alcohol can exacerbate hypotension.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
TECZEM (enalapril maleate and felodipine) is contraindicated in pregnancy. ACE inhibitors can cause fetal and neonatal morbidity and death when administered to pregnant women. First trimester exposure may be associated with a small increased risk of congenital anomalies; second and third trimester exposure is associated with oligohydramnios, fetal renal dysfunction, skull ossification defects, and neonatal hypotension, anuria, and renal failure. Felodipine: No teratogenic effects in animal studies at clinically relevant doses; however, limited human data. Combined use should be avoided in pregnancy.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
Enalapril is excreted in human milk in trace amounts; the M/P ratio is approximately 0.01. Felodipine is excreted in human milk; the M/P ratio is unknown. Due to potential for adverse effects in the nursing infant, especially renal effects from enalapril, breastfeeding is not recommended during TECZEM therapy.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
TECZEM is contraindicated in pregnancy. If a woman becomes pregnant while on TECZEM, discontinue the drug immediately. No dose adjustments are recommended as the drug should not be used. Alternative antihypertensive therapy should be considered if needed.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
TECZEM (enalapril/diltiazem ER) combines an ACE inhibitor and a non-dihydropyridine calcium channel blocker. Monitor renal function and serum potassium; avoid in patients with pre-existing high-grade AV block or severe left ventricular dysfunction. Use with caution in patients with hepatic impairment due to diltiazem metabolism. May cause reflex tachycardia less frequently than dihydropyridines.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Take this medication exactly as prescribed; do not crush or chew the extended-release tablet.,Monitor blood pressure regularly and report symptoms such as dizziness, fainting, or irregular heartbeat.,Avoid salt substitutes containing potassium unless directed by your doctor.,Report any signs of angioedema (swelling of face, lips, tongue, or difficulty breathing) immediately.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TECZEM vs ALDOCLOR-250, answered by our medical review team.
TECZEM is a Antihypertensive combination that works by Enalapril inhibits angiotensin-converting enzyme (ACE), reducing angiotensin II formation, leading to vasodilation and decreased aldosterone secretion. Diltiazem inhibits calcium ion influx across cardiac and smooth muscle cells, causing coronary vasodilation and decreased myocardial contractility.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TECZEM and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TECZEM is: 1 to 2 tablets (enalapril 5 mg/diltiazem 180 mg) orally once daily. Maximum: 2 tablets daily.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TECZEM and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TECZEM is classified as Category C. TECZEM (enalapril maleate and felodipine) is contraindicated in pregnancy. ACE inhibitors can cause fetal and neonatal morbidity and death when administered to pregnant women. Firs. ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.